Authors
Latest:
Immunotherapeutic Approaches to the Management of Head and Neck CancerExperts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Latest:
Immunotherapeutic Approaches to the Management of Head and Neck CancerExperts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Latest:
Immunotherapeutic Approaches to the Management of Head and Neck CancerExperts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Latest:
Strategies for the Optimal Management of Dyspnea in Cancer Patients With Advanced IllnessIn this article, Dr. Mona Patel discusses how to best manage dyspnea in cancer patients, with both pharmacologic and nonpharmacologic approaches.
Latest:
Identifying Molecular Markers of Relapse in Myelodysplastic SyndromeIn this month's installment of Ask the PI, ONCOLOGY spoke with Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists.
Latest:
Identifying Molecular Markers of Relapse in Myelodysplastic SyndromeIn this month's installment of Ask the PI, ONCOLOGY spoke with Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists.
Latest:
COUNTERPOINT-Prostate Cancer Genomic Analysis: Routine or Research Only?In this side of the Point/Counterpoint, Drs. Kelly and Knudsen state that limitations exist for guiding therapeutic treatment with genomic testing in prostate cancer patients.
Latest:
Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS MalignanciesThis article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.
Latest:
Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS MalignanciesThis article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.
Latest:
Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS MalignanciesThis article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.
Latest:
Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS MalignanciesThis article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.
Latest:
Gonadotropin-Releasing Hormone Antagonists in Prostate CancerThis article reviews the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix, as well as its potential risks and benefits, particularly when it comes to cardiovascular health.
Latest:
Gonadotropin-Releasing Hormone Antagonists in Prostate CancerThis article reviews the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix, as well as its potential risks and benefits, particularly when it comes to cardiovascular health.
Latest:
Managing Afib in Cancer Patients Taking BTK InhibitorsCancer Network speaks with Dr. Leon Ptaszek about managing cancer patients who have atrial fibrillation and are being treated with BTK inhibitors.
Latest:
KATHERINE Results Back New Adjuvant Standard for HER2+ Breast CancerDr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.
Latest:
Targeting PI3K Remains Complex in Cancer TherapyDr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy.
Latest:
Interrogating Ras-ERK Interactions and Roles in Tumor Cell BiologyCancer Network spoke with Dr. Chuan-Hsiang Huang about his lab’s research on Ras-ERK protein interactions within cancer cells.
Latest:
Identifying Cancer-Driving Gene MutationsCancer Network spoke with Dr. Rachel Karchin about the contemporary search for cancer-driving gene mutations.
Latest:
Promising Glioma Therapy OptionsDr. James Perry speaks with Cancer Network about glioma therapy options and the future of brain cancer treatment.
Latest:
Discussing Advances in Chemo Brain TreatmentCancer Network spoke with Tracy D. Vannorsdall, PhD and Patricia Ganz, MD about treatment methods for cancer-related cognitive impairment.
Latest:
Discussing Advances in Chemo Brain TreatmentCancer Network spoke with Tracy D. Vannorsdall, PhD and Patricia Ganz, MD about treatment methods for cancer-related cognitive impairment.
Latest:
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial CancerIn this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.
Latest:
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial CancerIn this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.
Latest:
Current Strategies for the Management of Locoregional Breast Cancer RecurrenceIn this review, we focus primarily on describing locoregional and systemic management strategies for isolated locoregional recurrences manifesting as isolated first-failure events following mastectomy or breast-conserving therapy.
Latest:
Current Strategies for the Management of Locoregional Breast Cancer RecurrenceIn this review, we focus primarily on describing locoregional and systemic management strategies for isolated locoregional recurrences manifesting as isolated first-failure events following mastectomy or breast-conserving therapy.
Latest:
Vitamin D and Omega-3 Supplements for Preventing Cancer and Other Chronic DiseasesDr. Manson discusses the results of the recently published VITAL study that tested whether vitamin D or omega-3 supplements could be effective for primary prevention of cancer and cardiovascular disease.
Latest:
Bexmarilimab Shows Survival Efficacy in Relapsed/Refractory MDSMore follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Latest:
Early Access to Electronic Health Records May Influence the Patient ExperienceIn a recent Hot Topics column, Mehmet Sitki Copur, MD, FACP, et al discussed the pros and cons of patients receiving test results early through electronic medical records.
Latest:
Locally Advanced Rectal Cancer, What is the Standard of Care?A 39-year-old Hispanic male presented with complaints of mucous stools, loss of appetite, rectal bleeding and a 30-pound weight loss within the past several months.
Latest:
Management of Neutropenic Toxicity From CDK4/6 InhibitorsAn oncology pharmacist discusses how to manage neutropenic toxicity from treatment with CDK4/6 inhibitors for HR-positive breast cancer.
